Keywords: آلک; irAE; immune related adverse event; ECOG PS; European cooperative oncology group performance status; n.s.; not significant; EGFR; epidermal growth factor receptor; ALK; anaplastic lymphoma kinase; PD-L1; programmed death-ligand 1; TKI; tyrosine-kinase inh
مقالات ISI آلک (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: آلک; Bone morphogenetic protein (BMP); Granulosa cells; Metformin; Smad and steroidogenesis; ActRII; activin type-II receptor; ALK; activin receptor-like kinase; AMPK; AMP-activated protein kinase; BMP; bone morphogenetic protein; BMPRII; BMP type-II receptor;
Keywords: آلک; AD; anaerobic digestion; ALK; alkalinity; CHONS; carbon, hydrogen, oxygen, nitrogen and sulfur; COD; chemical oxygen demand; CSTR; continuously stirred tank reactor; C:N; carbon to nitrogen ratio; DGGE; denaturing gradient gel electrophoresis; HAc; acetic
Keywords: آلک; PD-1; programed cell death-1; PD-L1; programmed cell death ligand 1; NSCLC; non-small-cell lung cancer; OS; overall survival; PFS; progression-free survival; ORR; objective response rate; irAEs; immune-related adverse events; RECIST; response evaluation c
Keywords: آلک; T; temperature; DO; dissolved oxygen; Cond; conductivity; TDS; total dissolved solids; Alk; alkalinity; TWH; total water hardness; N-NO2-; nitrite; N-NO3-; nitrate; P-PO43-; orthophosphate; COD; chemical oxygen demand; SE; standard error; M-W U-test; Man-
Keywords: آلک; Alk; alkalinity; ANN; artificial neural network; AO-MBR; anoxic-aerobic membrane bioreactor; COD; chemical oxygen demand; DO; dissolved oxygen; HRT; hydraulic retention time; MBR; membrane bioreactor; MLSS; mixed liquor suspended solids; MLVSS; mixed liqu
Keywords: آلک; Histone methylation; Histone demethylation; Lung cancer; Histone methyltransferase; Histone demethylase; Inhibitors; ALK; anaplastic lymphoma kinase; DUSP3; dual-specificity phosphatase 3; Elk1; ETS-domain containing protein; EMT; epithelial-to-mesenchyma
Keywords: آلک; NSCLC; Non-Small Cell Lung Carcinoma; SCLC; Small Cell Lung Carcinoma; AC; Adenocarcinoma; LCT; Lung Carcinoid Tumor; LCC; Large Cell Carcinoma; CTC; Circulating Tumor Cells; UICC; The Union for International Cancer Control; CT; Computer-based Tomography;
Keywords: آلک; 5-FU; 5-fluorouracil; AF; atrial fibrillation; ALK; anaplastic lymphoma kinase; APD; action potential duration; APL; acute promyelocytic leukemia; BCR-ABL; breakpoint cluster region-Abelson; BTK; Bruton tyrosine kinase; CD20; cluster of differentiation 20
Keywords: آلک; MW; Microwave; Ext; Extrusions; Frz; Freezing; Acd; Acid pretreatment; Oxd; Oxidative pretreatment; Alk; Alkaline pretreatment; IL; Ionic liquid pretreatment; Orgv; Organosolv pretreatment; AFExp; Ammonia fibre explosion; US; Ultrasonication; SExp; Steam
Keywords: آلک; ALK; Anaplastic Lymphoma Kinase; CI; Confidence interval; CT; Computerized Tomography; EGFR; Epidermal Growth Factor Receptor; ESMO; European Society of Medical Oncology; 18F-FDG; Fluorodeoxyglucose; IQR; Interquartile range; MATV; Metabolic Active Tumor
Keywords: آلک; FOP; POH; AHO; GNAS; Gsα; ACVR1; Trauma-induced; Neurogenic; TGF-β; Osteoblast; XLαs; NESP55; Imprint; Osseous metaplasia; Malignancies; ALK; BMP; Gli; PTHrP; Hedgehog;
Keywords: آلک; NSCLC; non-small cell lung cancer; EGFR; epidermal growth factor receptor; OR; odds ratio; HR; hazards ratio; CI; confidence interval; ALK; anaplastic lymphoma kinase; OS; overall survival; NHIS; National Health Insurance Service; NHID; National Health In
Keywords: آلک; AAPC; Average Annual Percent Change; ALK; anaplastic large-cell lymphoma kinase; ANVISA; Brazilian Health Surveillance Authorities; APC; annual percent change; EGFR; epidermal growth factor receptor mutations; FOSP; São Paulo Cancer Foundation; IBGE; Bra
Keywords: آلک; AE; adverse event; ALK; anaplastic lymphoma kinase; aNSCLC; advanced non-small cell lung cancer; DRG; diagnosis-related group; EGFR; epidermal growth factor receptor; GLM; generalized linear model; HMO; health maintenance organization; HR; hazard ratio; I
Keywords: آلک; ALK; anaplastic lymphoma kinase; ATP; adenosine triphosphate; BCR-ABL; Breakpoint cluster region-Abelson; DMEM; Dulbecco Modified Eagle Medium; EGFR; epidermal growth factor receptor; FUCCI; Fluorescence Ubiquitination Cell Cycle Indicator; HER; human e
Keywords: آلک; ALK; anaplastic lymphoma kinase; CAF; cancer-associated fibroblast; CSC; cancer stem cell; CRC; colorectal cancer; EMT; epithelial-to-mesenchymal transition; EGFR; epidermal growth factor receptor; HH; hedgehog; HGF; hepatocyte growth factor; IGF; insulin
Keywords: آلک; AC; adenylate cyclase; ALK; activin receptor-like kinase; ActRII; activin type-II receptor; BMP; bone morphogenetic protein; BMPRII; BMP type-II receptor; FSH; follicle-stimulating hormone; FSHR; FSH receptor; GDF; growth and differentiation factor; GIP;
Keywords: آلک; NSCLC; non-small-cell lung cancer; PDX; patient-derived xenograft model; ALK; anaplastic lymphoma kinase; YHIM; Yonsei Human In Mouse; MAF; mutant allele frequency; H&E; hematoxylin and eosin; Non-small-cell lung cancer; Patient-derived xenograft; Preclin
Keywords: آلک; Neuroblastoma; Targeted therapy; Investigational drugs; MYCN; ALK; Ras/MAPK; Clinical trial; Immunotherapy;
Keywords: آلک; ALK; alkaline phosphatase; ALT; alanine amino transferase; DVT; Deep Vein Thrombosis; FDG PET/CT; 18F-Fluorodesoxyglucose Positron-Emission-Tomography combined with Computed-Tomography; GGT; gamma-glutamyl transpeptidase; PE; Pulmonary Embolism; VTE; Ve
Keywords: آلک; Lung adenocarcinoma; Epidermal growth factor receptor gene mutation; Adrenocortical carcinoma; Menin; Multiple endocrine neoplasia type 1; Immunohistochemistry; ACC; adrenocortical carcinoma; ALK; anaplastic lymphoma kinase; CT; computed tomography; EGFR;
Keywords: آلک; ALK; anaplastic lymphoma kinase; CB; cell block; EBUS-GS; endobronchial ultrasonography with guide sheath; EBUS-TBB; endobronchial ultrasonography-guided transbronchial lung biopsy; TBB; transbronchial lung biopsy; Aspiration method; Bronchoscopy; Cell bl
Keywords: آلک; ALK; activin receptor-like kinase; ActRI; activin type-I receptor; ActRII; activin type-II receptor; BMP; bone morphogenetic protein; BMPRI; BMP type-I receptor; BMPRII; BMP type-II receptor; FSH; follicle-stimulating hormone; FSHR; FSH receptor; GDF; gro
Keywords: آلک; ALK; anaplastic lymphoma kinase; CTLs; cytotoxic T lymphocytes; DLBCL; diffuse large B-cell lymphoma; ECOG-PS; Eastern Cooperative Oncology Group Performance Status; mAb; monoclonal antibody; NSCLC; non-small cell lung cancer; non-SQC; non-squamous cell l
Keywords: آلک; ALK; anaplastic lymphoma kinase; DCTN1; dynactin 1; EGFR; epidermal growth factor receptor; EML4; microtubule-associated protein-like 4; FISH; fluorescence in situ hybridization; GLCI; Guangdong Lung Cancer Institute; HELP; hydrophobic EMAP-like protein;
Keywords: آلک; EGFR; Epidermal growth factor receptor; TP53; Tumor protein p53; KRAS; Kirsten rat carcoma viral oncogene; ALK; Anaplastic lymphoma kinase; RTK; Protein receptor tyrosine kinase; TKI; Tyrosine kinase inhibitor; PI3K; Phosphatidylinositol 3-kinase; NSCLC;
Keywords: آلک; MCFA; medium chain fatty acid; FAS; fatty acid synthase; Headspace/SPME/GC/MS; Headspace/solid-phase microextraction/gas chromatography/mass spectrometry; ADO; aldehyde deformylating oxygenase; CAR; carboxylic acid reductase; Medium-chain fatty acids; Alk
Keywords: آلک; adenocarcinoma; ALK; EGFR; molecular pathology; non-small cell lung cancer; pathology; PD-L1; ROS1;
Keywords: آلک; ALK; EGFR; Molecular markers; Screening; Targeted therapy;
Keywords: آلک; Bottom ash; Co-landfill; Leachate treatment; Leachate collection system clogging; MSW; municipal solid waste; BA; bottom ash; FA; fly ash; LCS; leachate collection system; ANC; acid neutralization capacity; TOC; total organic carbon; VFA; volatile fatty a
Keywords: آلک; ALK; anaplastic lymphoma kinase; CNS; central nervous system; EGFR; epidermal growth factor receptor; FDA; food and drug administration; GCN; gene copy number; HGF; hepatocyte growth factor; IC50; half inhibitory concentration; IHC; immunohistochemistry;
Keywords: آلک; SNPs; single-nucleotide polymorphisms; EGFR; epidermal growth factor receptor; NSCLC; non-small cell lung cancer; ADC; lung adenocarcinoma; LCINS; lung cancer in never-smokers; ALK; anaplastic lymphoma kinase; GWAS; genome-wide association studies; HKU/HA
Keywords: آلک; AL; alcohols; ALK; alkenones; ANOSIM; analysis of similarities; DW; dry weight; EFA; essential fatty acid; FA; fatty acid; FAME; fatty acid methyl esters; FCM; flow cytometry; FFA; free fatty acids; FSC; forward scatter; GE; glyceryl ethers; HC; hydrocarb
Keywords: آلک; 7AAD; 7-aminoactinomycin D; αSMA; alpha smooth muscle actin; AKT; protein kinase B; ALK; activin receptor-like kinase; Ang; angiopoietin; Ang II; angiotensin II; BCRP1; breakpoint cluster region pseudogene; bFGF; basic fibroblast growth factor; C1P; cera
Keywords: آلک; AC; articular cartilage; Akt; RAC-alpha serine/threonine-protein kinase; AGE; advanced glycation end products; ALK; activin receptor-like kinase; APO-A; apolipoprotein A; BMP; bone morphogenetic protein; CRP; C-reactive protein; ECM; extracellular matrix;
Keywords: آلک; ActRI; activin type-I receptor; ActRII; activin type-II recepto; ALK; activin receptor-like kinase; AR; androgen receptor; BMP; bone morphogenetic protein; BMPRI; BMP type-I receptor; BMPRII; BMP type-II receptor; DBH; dopamine-β-hydroxylase; DDC; 3,4-di
Keywords: آلک; ACVR; activin A receptor; ALK; activin receptor-like kinase; BMP; bone morphogenetic protein; BOP; blast over pressure; COX; cyclo-oxygenase; CT; computed tomography; ECM; extracellular matrix; FOP; fibrodysplasia ossificans progressiva; HES; hydroxy-ethy
Keywords: آلک; 1°amine; primary amine; 2°amine; secondary amine; 3°amine; tertiary amine; Ac; acetyl group; Alk; alkyl group; APTMS; aminopropyltrimethoxysilane; BF; base formulation; cP; centipoise; DABCO®; 1,4-diazobicyclo [2.2.2] octane; DBU; 1,8-diazabicyclo[5.4
Keywords: آلک; ALK; anaplastic lymphoma receptor tyrosine kinase; ABCB1; ATP-binding cassette, sub-family B (MDR/TAP), member 1; APE1; apurinic/apyimidinic endonuclease 1; AKT; v-akt murine thymoma viral oncogene; BER; base excision repair; BRCA1; breast cancer 1; BRCA2
Keywords: آلک; Non-small cell lung cancer (NSCLC); Personalized medicine; EGFR; ALK; Early detection; Video-assisted thoracoscopic surgery (VATS); Stereotactic ablative radiotherapy (SABR); Immunotherapy
Keywords: آلک; ALK; Scaffold morphing; Hinge; Karpas299
Keywords: آلک; ALK; anterior lamellar keratoplasty; DSEK; Descemet's stripping endothelial keratoplasty; EK; endothelial keratoplasty; HR; hazard ratio; IOL; intraocular lens; IOP; intraocular pressure; PAS; peripheral anterior synechiae; PK; penetrating keratoplasty;
Keywords: آلک; Adjuvant therapy; ALK; EGFR; Genetic markers; Lung cancer; Metastatic spine disease;
Keywords: آلک; 2-AG; 2-arachidonoylglycerol; ALK; anaplastic lymphoma kinase; ATF-4; activating transcription factor 4; CB1; cannabinoid CB1 receptor; CB2; cannabinoid CB2 receptor; CBD; cannabidiol; CHOP; C/EBP homologous protein; EGFR; epidermal growth factor receptor
Keywords: آلک; ALK; alkaline phosphatase; BMP-2; bone morphogenetic protein-2; MGP; matrix γ-carboxyglutamic acid protein; NO; nitric oxide; OPN; osteopontin; PLLA; poly-l-lactide; PLGA; poly-d,l-lactide-co-glycolide; O2â¿¿; superoxide anion; Biodegradable materials; B
Keywords: آلک; Acquired cystic disease-associated RCC; ALK; anaplastic lymphoma kinase; atrophic kidney-like renal tumour; Birt–Hogg–Dubé syndrome-associated renal tumour; clear cell papillary RCC; HLRCC associated RCC; succinate dehydrogenase-deficient RCC; thyroid-lik
Keywords: آلک; Lung carcinoma; Lung adenocarcinoma; EGFR; KRAS; ALK; MET; Histology
Keywords: آلک; ALK; anaplastic lymphoma kinase; ALL; acute lymphoblastic leukemia; CLL; chronic lymphocytic leukemia; CML; chronic myelogenous leukemia; CNS; central nervous system; CRC; colorectal cancer; DTC; differentiated thyroid carcinoma; DUSP; dual specificity ph
Keywords: آلک; Targeted receptor TKIs; Acquired resistance to receptor TKIs; Overcoming drug resistance; Driver oncogenes; Gate keeper receptor mutations; Bypass signaling molecules; ABC; ATP-binding cassette; AKT/PKB; Protein kinase B; ALK; Anaplastic lymphoma kinase;